[go: up one dir, main page]

WO2001074787A3 - Produit pharmaceutique cristallise - Google Patents

Produit pharmaceutique cristallise Download PDF

Info

Publication number
WO2001074787A3
WO2001074787A3 PCT/US2001/009112 US0109112W WO0174787A3 WO 2001074787 A3 WO2001074787 A3 WO 2001074787A3 US 0109112 W US0109112 W US 0109112W WO 0174787 A3 WO0174787 A3 WO 0174787A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline pharmaceutical
crystalline
pharmaceutical
lopinavir
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/009112
Other languages
English (en)
Other versions
WO2001074787A2 (fr
Inventor
Daniel A Dickman
Sanjay Chemburkar
James J Fort
Rodger F Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001074787(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Priority to CNB018076882A priority Critical patent/CN1330639C/zh
Priority to PL35972701A priority patent/PL359727A1/xx
Priority to AU5092001A priority patent/AU5092001A/xx
Priority to SK1483-2002A priority patent/SK14832002A3/sk
Priority to MXPA02009559A priority patent/MXPA02009559A/es
Priority to IL15155101A priority patent/IL151551A0/xx
Priority to CA002403635A priority patent/CA2403635A1/fr
Priority to HU0302675A priority patent/HUP0302675A3/hu
Priority to AU2001250920A priority patent/AU2001250920B2/en
Priority to BR0109433-5A priority patent/BR0109433A/pt
Priority to KR1020027012849A priority patent/KR100773258B1/ko
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to EP01924250A priority patent/EP1268442A2/fr
Priority to NZ521183A priority patent/NZ521183A/en
Priority to JP2001572482A priority patent/JP2003529592A/ja
Publication of WO2001074787A2 publication Critical patent/WO2001074787A2/fr
Publication of WO2001074787A3 publication Critical patent/WO2001074787A3/fr
Priority to ZA200206962A priority patent/ZA200206962B/en
Priority to NO20024679A priority patent/NO325005B1/no
Anticipated expiration legal-status Critical
Priority to BG107165A priority patent/BG107165A/bg
Priority to AU2006222711A priority patent/AU2006222711A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des nouvelles formes cristallines de lopinavir.
PCT/US2001/009112 2000-03-30 2001-03-21 Produit pharmaceutique cristallise Ceased WO2001074787A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
NZ521183A NZ521183A (en) 2000-03-30 2001-03-21 Crystalline form of lopinavir
JP2001572482A JP2003529592A (ja) 2000-03-30 2001-03-21 結晶性医薬
KR1020027012849A KR100773258B1 (ko) 2000-03-30 2001-03-21 결정성 약제
AU5092001A AU5092001A (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
SK1483-2002A SK14832002A3 (sk) 2000-03-30 2001-03-21 Kryštalické liečivo
MXPA02009559A MXPA02009559A (es) 2000-03-30 2001-03-21 Producto farmaceutico cristalino.
IL15155101A IL151551A0 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
CA002403635A CA2403635A1 (fr) 2000-03-30 2001-03-21 Produit pharmaceutique cristallise
EP01924250A EP1268442A2 (fr) 2000-03-30 2001-03-21 Produit pharmaceutique cristallise
PL35972701A PL359727A1 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
BR0109433-5A BR0109433A (pt) 2000-03-30 2001-03-21 Substância farmacêutica cristalina
CNB018076882A CN1330639C (zh) 2000-03-30 2001-03-21 晶体药物
AU2001250920A AU2001250920B2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
HU0302675A HUP0302675A3 (en) 2000-03-30 2001-03-21 New crystalline modifications of lopinavir
ZA200206962A ZA200206962B (en) 2000-03-30 2002-08-29 Crystalline pharmaceutical.
NO20024679A NO325005B1 (no) 2000-03-30 2002-09-30 Krystallinske former av lopinavir, farmasoytiske sammensetninger omfattende disse og deres anvendelse
BG107165A BG107165A (bg) 2000-03-30 2002-10-03 Кристални фармацевтични форми
AU2006222711A AU2006222711A1 (en) 2000-03-30 2006-09-27 Crystalline pharmaceutical

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/538,257 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
US09/793,536 2001-02-27

Publications (2)

Publication Number Publication Date
WO2001074787A2 WO2001074787A2 (fr) 2001-10-11
WO2001074787A3 true WO2001074787A3 (fr) 2002-02-07

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009112 Ceased WO2001074787A2 (fr) 2000-03-30 2001-03-21 Produit pharmaceutique cristallise

Country Status (22)

Country Link
EP (1) EP1268442A2 (fr)
JP (1) JP2003529592A (fr)
KR (1) KR100773258B1 (fr)
CN (2) CN101066952A (fr)
AR (2) AR033360A1 (fr)
AU (3) AU5092001A (fr)
BG (1) BG107165A (fr)
BR (1) BR0109433A (fr)
CA (1) CA2403635A1 (fr)
CZ (1) CZ20023529A3 (fr)
HU (1) HUP0302675A3 (fr)
IL (1) IL151551A0 (fr)
MX (1) MXPA02009559A (fr)
MY (1) MY128296A (fr)
NO (1) NO325005B1 (fr)
NZ (1) NZ521183A (fr)
PE (1) PE20011232A1 (fr)
PL (1) PL359727A1 (fr)
SA (2) SA01220270B1 (fr)
SK (1) SK14832002A3 (fr)
TW (1) TWI284640B (fr)
WO (1) WO2001074787A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058433B2 (en) 2000-03-30 2011-11-15 Abbott Laboratories Crystalline pharmaceutical

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
WO2011025849A1 (fr) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Procédés de préparation d’inhibiteurs de protéase du virus de l’hépatite c
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057648A1 (fr) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (fr) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058433B2 (en) 2000-03-30 2011-11-15 Abbott Laboratories Crystalline pharmaceutical

Also Published As

Publication number Publication date
NO325005B1 (no) 2008-01-14
CA2403635A1 (fr) 2001-10-11
CN1330639C (zh) 2007-08-08
NO20024679D0 (no) 2002-09-30
AU2006222711A1 (en) 2006-10-19
KR100773258B1 (ko) 2007-11-05
MY128296A (en) 2007-01-31
SK14832002A3 (sk) 2003-02-04
WO2001074787A2 (fr) 2001-10-11
HUP0302675A3 (en) 2004-03-29
TWI284640B (en) 2007-08-01
MXPA02009559A (es) 2003-05-21
NZ521183A (en) 2004-03-26
IL151551A0 (en) 2003-04-10
NO20024679L (no) 2002-09-30
AU5092001A (en) 2001-10-15
BR0109433A (pt) 2004-08-10
AR033360A1 (es) 2003-12-17
JP2003529592A (ja) 2003-10-07
CZ20023529A3 (cs) 2003-02-12
BG107165A (bg) 2003-07-31
KR20030011807A (ko) 2003-02-11
EP1268442A2 (fr) 2003-01-02
AU2001250920B2 (en) 2006-06-29
SA01220270B1 (ar) 2006-11-14
PE20011232A1 (es) 2001-12-08
SA06270303B1 (ar) 2009-08-02
CN1422259A (zh) 2003-06-04
AR049560A2 (es) 2006-08-16
PL359727A1 (en) 2004-09-06
CN101066952A (zh) 2007-11-07
HUP0302675A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
WO2003035617A3 (fr) Derives de l'uk-2a
AU781269C (en) Pharmaceutical compositions
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001270778A1 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2001282174A1 (en) Method for the production of xylitol
AU2002232468A1 (en) Pharmaceutical heterocyclic compounds
AU2001248943A1 (en) Pharmaceutical curative compound
AU2002359518A1 (en) Efavirenz tablet formulation having unique biopharmaceutical characteristics
AU2001273919A1 (en) Pharmaceutical compositions
WO2002060906A3 (fr) Modification de cristaux
AU2001266081A1 (en) Improvement of itraconazole bioavailability
AU2002352357A1 (en) Trioxane derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2002353659A1 (en) Simvastatin dosage forms
AU2002333276A1 (en) Drugs for vasculopaties
WO2001074787A3 (fr) Produit pharmaceutique cristallise
AU2001265935A1 (en) Production of biohydrolysates
AU2001285667A1 (en) Sanitary cigarette case
AU2001277728A1 (en) Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
AU2001292578A1 (en) Pharmaceutical compounds
AU2001264900A1 (en) Pharmaceutical use of fibulin-1
AU2001288484A1 (en) Novel metallotexaphyrin derivatives
AU2002342940A1 (en) New pharmaceutical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002/06962

Country of ref document: ZA

Ref document number: 200206962

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 151551

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 521183

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001250920

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2403635

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 02086628

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2001 572482

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009559

Country of ref document: MX

Ref document number: 1020027012849

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018076882

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001924250

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 107165

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14832002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2002-3529

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001924250

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027012849

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-3529

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 521183

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521183

Country of ref document: NZ